source
- Government policies strain funding and operations for small biotech firmsCassel Salpeter's latest healthcare investment report says that recent government actions, including FDA staff reductions, slower federal research grants and higher tariffs, are creating a tough fu…
- FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failureThe U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…